{"gene":"ADRB2","run_date":"2026-06-09T22:02:42","timeline":{"discoveries":[{"year":2016,"finding":"ADRB2 signaling negatively regulates autophagy by disrupting the Beclin1/VPS34/Atg14 complex in an Akt-dependent manner, leading to HIF1α stabilization through inhibition of autophagic degradation, reprogramming of HCC cell glucose metabolism, and acquisition of sorafenib resistance. Knockdown of ADRB2 enhanced autophagy and destabilized HIF1α.","method":"Immunoblotting, immunofluorescence, immunoprecipitation, knockdown/inhibitor studies in HCC cell lines and nude mouse xenografts","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP of Beclin1/VPS34/Atg14 complex disruption, multiple orthogonal methods (immunoprecipitation, immunoblot, in vivo xenograft, genetic knockdown and pharmacologic inhibition), replicated across cell lines and mouse model","pmids":["27154061"],"is_preprint":false},{"year":2011,"finding":"HIC1 (Hypermethylated in Cancer 1) is a direct transcriptional repressor of ADRB2. Loss of HIC1 in breast cancer cells leads to upregulation of ADRB2, and agonist-mediated stimulation of ADRB2 increases migration and invasion of MDA-MB-231 cells; these effects are abolished by HIC1 re-expression or ADRB2 siRNA knockdown.","method":"Promoter luciferase assay, chromatin immunoprecipitation (ChIP), sequential ChIP, siRNA knockdown, migration/invasion assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP demonstrating HIC1 binding to ADRB2 promoter, luciferase reporter, sequential ChIP, functional rescue experiments with siRNA","pmids":["22194601"],"is_preprint":false},{"year":2014,"finding":"Mechanical compressive force upregulates Adrb2 expression in human periodontal ligament cells (PDLCs) via elevation of intracellular Ca2+ concentration. Activation of Adrb2 in PDLCs increases the RANKL/OPG ratio and promotes peripheral blood mononuclear cell differentiation into osteoclasts, thereby facilitating bone resorption and orthodontic tooth movement.","method":"In vitro compressive force application to primary PDLCs, intracellular Ca2+ measurement, RANKL/OPG ratio assay, co-culture osteoclastogenesis assay, Adrb1/2 knockout mice, superior cervical ganglionectomy in rats","journal":"Journal of dental research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout mice (Adrb1/2−/−), pharmacologic manipulation, mechanistic cell assays, and in vivo orthodontic model with multiple orthogonal methods","pmids":["25252876"],"is_preprint":false},{"year":2017,"finding":"α-Ketoglutarate (AKG) inhibits PHD3 expression and blocks PHD3-ADRB2 interaction, thereby increasing ADRB2 protein stability. AKG rescues skeletal muscle atrophy and protein degradation through this PHD3/ADRB2-mediated mechanism.","method":"Pharmacological and genetic approaches (PHD3 inhibition/knockdown), co-immunoprecipitation of PHD3-ADRB2, corticosterone-induced atrophy model, Duchenne muscular dystrophy mouse model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying PHD3-ADRB2 interaction, genetic and pharmacologic rescue in vivo, single lab with two orthogonal approaches","pmids":["28939592"],"is_preprint":false},{"year":2018,"finding":"Pancreas-specific deletion of Adrb2 results in glucose intolerance and impaired insulin secretion specifically in female mice. Mechanistically, neonatal Adrb2 loss increases VEGF-A production in female neonatal β-cells, causing hyper-vascularized islets during development that disrupts insulin production and exocytosis. Neonatal VEGF-A receptor blockade fully rescues the glucose homeostasis deficits.","method":"Conditional knockout (nestin-Cre and pancreas-specific Cre x Adrb2 flox mice), glucose tolerance tests, insulin secretion assays, VEGF-A measurement, VEGFR blockade rescue experiments","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional knockout with multiple phenotypic readouts, mechanistic rescue by VEGFR blockade, sex-specific and developmental-stage-specific dissection","pmids":["30303066"],"is_preprint":false},{"year":2020,"finding":"Conditional deletion of Adrb2 specifically in nestin+ mesenchymal stem cells attenuates subchondral bone loss and cartilage degradation in a temporomandibular joint osteoarthritis model, demonstrating that Adrb2 signaling in MSCs promotes osteoclastogenesis and subchondral bone remodeling.","method":"Nestin-Cre x Adrb2 flox conditional knockout mice, unilateral anterior crossbite model, histomorphometry, bone mineral density, osteoclast surface quantification, pro-osteoclastic factor expression","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional knockout with detailed quantitative histomorphometric phenotyping across multiple bone and cartilage parameters","pmids":["31926929"],"is_preprint":false},{"year":2022,"finding":"ERAP1 (hepatokine endoplasmic reticulum aminopeptidase 1) physically interacts with ADRB2 and reduces ADRB2 protein expression by decreasing USP33 (ubiquitin-specific peptidase 33)-mediated deubiquitination, thereby interrupting ADRB2-stimulated insulin signaling in skeletal muscle.","method":"Co-immunoprecipitation of ERAP1-ADRB2 interaction, USP33 knockdown/overexpression, hepatic ERAP1 overexpression and knockdown in mice, insulin sensitivity assays","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP identifying ERAP1-ADRB2 interaction, deubiquitinase (USP33) identified as ADRB2 writer/eraser, in vivo genetic manipulation with functional metabolic readouts","pmids":["35192681"],"is_preprint":false},{"year":2010,"finding":"ADRB2 haplotypes constructed from 26 polymorphisms across the entire intronless gene (promoter, 5'UTR, coding, 3'UTR) drive differential cell-surface β2AR protein expression and agonist-promoted downregulation in a haplotype-dependent manner when expressed in COS-7 cells.","method":"Whole-gene haplotype transfection into COS-7 cells, radioligand binding for cell-surface receptor quantification, agonist-promoted downregulation assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based transfection with quantitative receptor expression and downregulation assays, single lab, multiple haplotypes tested","pmids":["20686604"],"is_preprint":false},{"year":2022,"finding":"Activation of the ADRB2/PKA signaling pathway enhances PPARγ expression and lipid synthesis in human meibomian gland epithelial cells (HMGECs). The ADRB2 agonist salbutamol increased PPARγ expression and lipid synthesis, while the ADRB2 antagonist timolol had the opposite effect, mediated through CREB phosphorylation.","method":"Pharmacological agonist/antagonist treatment of HMGECs, immunoblotting for CREB phosphorylation, PPARγ and SREBP-1 expression, LipidTOX staining, AdipoRed assay, Oil Red O staining","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacologic activation and inhibition of ADRB2 with multiple lipid synthesis readouts, single lab, two orthogonal methods","pmids":["36012741"],"is_preprint":false},{"year":2023,"finding":"Aerobic exercise activates ADRB2/β2-adrenergic receptor signaling, which reverses autophagy-lysosomal deficits by upregulating VMA21 levels to restore V-ATPase function, reducing amyloid-β pathology in APP-PSEN1 mice. Propranolol (ADRB2 antagonist) blocked these exercise-induced benefits.","method":"Aerobic exercise intervention in APP-PSEN1 transgenic mice, propranolol pharmacologic blockade, AMPK-mTOR pathway analysis, VMA21 expression, amyloid-β quantification, cognitive testing","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic/pharmacologic ADRB2 manipulation in transgenic disease model, pathway analysis with multiple molecular readouts, single lab","pmids":["37964627"],"is_preprint":false},{"year":2019,"finding":"PM2.5 exposure causes ADRB2 promoter hypermethylation, reducing β2AR expression and inhibiting PI3K/Akt signaling, which activates Bcl-2/BAX and p53 apoptotic pathways in cardiomyocytes. ADRB2 overexpression attenuated PM2.5-induced apoptosis, an effect abolished by PI3K inhibitor LY294002.","method":"DNA methylation chip and bisulfite sequencing PCR (BSP) in AC16 cardiomyocytes, ADRB2 overexpression transgenic cell lines, PI3K inhibitor LY294002, TUNEL assay, rat intratracheal instillation model, echocardiography","journal":"Environment international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epigenetic mechanism (methylation) identified with BSP, functional rescue by ADRB2 overexpression and pathway inhibition, in vivo model corroboration, single lab","pmids":["30986742"],"is_preprint":false},{"year":2018,"finding":"ADRB2 Gly16 allele carriers with heart failure show defective β2AR-coupled inhibitory Gi protein signaling in vitro, and Gly16 allele carriers show beneficial response to β-blocker therapy in a dose-dependent manner, whereas Arg16 homozygotes show no response.","method":"In vitro signaling assays for Gi coupling, multicenter cohort study (2403 + 919 patients), genotype-stratified analysis of clinical outcomes","journal":"Cell discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro Gi signaling experiment plus large independent clinical validation cohort, single mechanistic assay but replicated clinically","pmids":["30374408"],"is_preprint":false},{"year":2018,"finding":"ADRB2 signaling promotes resistance to VEGFR2-TKIs in non-small cell lung cancer via upregulation of ADRB2/VEGFR2 interaction and activation of the ADRB2/CREB/PSAT1 signaling pathway. Pharmacologic ADRB2 inhibition (propranolol) sensitized NSCLC cells to VEGFR2-TKIs in vitro and in vivo.","method":"Co-immunoprecipitation of ADRB2/VEGFR2 interaction, ADRB2 inhibitor (propranolol) treatment in NSCLC cell lines and xenograft models, CREB/PSAT1 pathway analysis","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for ADRB2/VEGFR2 interaction, pharmacologic and in vivo validation, single lab with multiple orthogonal methods","pmids":["35075132"],"is_preprint":false},{"year":2019,"finding":"ADRB2 activation by epinephrine/norepinephrine in gastric cancer cells promotes proliferation, invasion, and metastasis through the ERK1/2-JNK-MAPK pathway and transcription factors NF-κB, AP-1, CREB, and STAT3. ADRB2-specific antagonist ICI118,551 reversed these effects; ADRB1 antagonist atenolol had no effect.","method":"Proliferation, migration, invasion, cell cycle, and apoptosis assays in GC cell lines; ERK1/2-JNK-MAPK pathway analysis; xenograft mouse models with chronic restraint stress; ICI118,551 and atenolol pharmacologic discrimination","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-subtype-specific pharmacologic discrimination, multiple downstream pathway readouts, in vivo xenograft model, single lab","pmids":["31624248"],"is_preprint":false},{"year":2019,"finding":"miR-15a-5p directly targets the ADRB2 3'UTR and reduces ADRB2 mRNA and protein expression in a dose-dependent manner. ADRB2 knockdown inhibited IL-13-induced expression of GM-CSF, eotaxin, and MUC5AC in nasal epithelial cells, and miR-15a-5p mediated its anti-inflammatory effect through ADRB2.","method":"Luciferase reporter assay (wild-type vs. mutant ADRB2 3'UTR), biotin pull-down assay, siRNA knockdown, ELISA, Western blotting in IL-13-stimulated human nasal epithelial cells","journal":"Human cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter with wild-type/mutant 3'UTR confirming direct miR-15a-5p targeting, functional knockdown rescue, single lab","pmids":["31104300"],"is_preprint":false},{"year":2025,"finding":"A subpopulation of ADRB2+ interstitial macrophages surrounding pulmonary sympathetic nerves responds to norepinephrine released via a CeA-RVLM-sympathetic neural pathway, amplifying inflammatory cytokine production and lung injury during severe pneumonia. Specific inhibition of pulmonary sympathetic nerves or ADRB2 signaling improved outcomes.","method":"Optogenetic/chemogenetic inhibition of CeA GABAergic neurons, sympathetic nerve manipulation, norepinephrine measurement, ADRB2+ macrophage identification and functional characterization, lethal pneumonia mouse model","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic and pharmacologic manipulations of neural circuit and ADRB2 in macrophages, in vivo disease model with survival and cytokine readouts, circuit-level mechanistic dissection","pmids":["40466637"],"is_preprint":false},{"year":2023,"finding":"ADRB2 inhibition suppresses TGF-β1-induced fibroblast-to-myofibroblast differentiation by suppressing SMAD2/3 activation and increasing phospho-SMAD2/3 proteasome degradation. Conversely, ADRB2 enhancement induces fibroblast-to-myofibroblast differentiation. ADRB2 inhibition attenuated bleomycin-induced lung fibrosis in vivo.","method":"ADRB2 knockdown/overexpression in lung fibroblasts, pSMAD2/3 immunoblotting, proteasome inhibitor experiments, bleomycin mouse model","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic gain- and loss-of-function with specific SMAD2/3 phosphorylation readout and proteasome pathway identification, in vivo model corroboration, single lab","pmids":["37923730"],"is_preprint":false},{"year":2012,"finding":"A functional SNP upstream of ADRB2 (rs34623097-A) reduces transcriptional activity of the ADRB2 promoter by approximately 10% and modulates nuclear factor binding affinity. The A allele was associated with increased obesity risk in Oceanic populations, consistent with reduced ADRB2 expression.","method":"Luciferase reporter assay comparing rs34623097-A vs. G allele, electrophoretic mobility shift assay (EMSA) for nuclear factor binding","journal":"International journal of obesity","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — luciferase reporter assay and EMSA providing functional characterization of SNP, single lab with two orthogonal methods","pmids":["23229733"],"is_preprint":false},{"year":2018,"finding":"A functional SNP upstream of ADRB2 (rs12654778) reduces relative ADRB2 promoter activity by ~26% (A vs. G allele) and modulates binding affinity of transcription factor neurofibromin 1 (NF1), establishing an allele-specific transcriptional regulatory mechanism linked to COPD susceptibility.","method":"Luciferase reporter assay, chromatin immunoprecipitation (ChIP) for NF1 binding, real-time PCR of ADRB2 expression in COPD patients vs. controls","journal":"International journal of chronic obstructive pulmonary disease","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — luciferase assay and ChIP demonstrating allele-specific promoter activity and TF binding, single lab with two orthogonal methods","pmids":["29588580"],"is_preprint":false},{"year":2024,"finding":"ADRB2 functions as an inhibitory checkpoint receptor on CAR-T cells. ADRB2 knockdown in CAR-T cells enhanced cytotoxicity against prostate cancer cells, increased CD69, CD107a, GzmB, IFN-γ, T-bet, and GLUT-1, improved proliferation, reduced apoptosis, and increased Bcl-2. The ZAP-70/NF-κB signaling axis was responsible for the improved functions. shβ2-CAR-T cells outperformed conventional CAR-T cells in vivo.","method":"RNAi knockdown of ADRB2 in CAR-T cells, cytotoxicity assays, flow cytometry for activation/exhaustion markers, ZAP-70/NF-κB pathway analysis, xenograft prostate cancer mouse model","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown with multiple functional readouts in vitro and in vivo, ZAP-70/NF-κB pathway mechanistically linked, single lab","pmids":["39228124"],"is_preprint":false}],"current_model":"ADRB2 (β2-adrenergic receptor) is a G-protein-coupled receptor that, upon activation by catecholamines, signals through cAMP/PKA and multiple downstream cascades (ERK/MAPK, PI3K/Akt, Gi protein) to regulate autophagy (by disrupting the Beclin1/VPS34/Atg14 complex), gene transcription (via CREB, NF-κB, AP-1, STAT3), lipid synthesis (via PKA/PPARγ), and protein stability (via PHD3 interaction and USP33-mediated deubiquitination); its expression is transcriptionally repressed by HIC1 and post-transcriptionally suppressed by miR-15a-5p and miR-16, while epigenetic silencing through promoter hypermethylation (e.g., induced by PM2.5) reduces receptor levels; in immune cells, ADRB2 acts as an inhibitory checkpoint on T cells through ZAP-70/NF-κB, and in ADRB2+ interstitial macrophages it amplifies inflammatory responses to sympathetic norepinephrine; in developmental contexts, neonatal β-cell ADRB2 restrains islet vascularization by suppressing VEGF-A, and in mesenchymal stem cells it promotes osteoclastogenesis and bone remodeling."},"narrative":{"mechanistic_narrative":"ADRB2 (β2-adrenergic receptor) is a catecholamine-responsive G-protein-coupled receptor whose signaling output is reused across metabolic, immune, skeletal, and oncogenic contexts to control autophagy, transcription, cell proliferation, and protein stability [PMID:27154061, PMID:31624248, PMID:40466637]. Through Akt-dependent signaling, ADRB2 disrupts the Beclin1/VPS34/Atg14 complex to suppress autophagy and stabilize HIF1α, reprogramming glucose metabolism and conferring sorafenib resistance in hepatocellular carcinoma [PMID:27154061]; in a context-dependent manner its activation can instead restore autophagy-lysosomal function by upregulating VMA21/V-ATPase to mitigate amyloid-β pathology [PMID:37964627]. In cancer cells, agonist-stimulated ADRB2 drives proliferation, invasion, and metastasis through the ERK1/2-JNK-MAPK cascade and the transcription factors NF-κB, AP-1, CREB, and STAT3 [PMID:31624248], and through ADRB2/VEGFR2 interaction and a CREB/PSAT1 axis it promotes resistance to VEGFR2-targeted therapy [PMID:35075132]. Through PKA-driven CREB phosphorylation it enhances PPARγ expression and lipid synthesis [PMID:36012741], and through Gi coupling it transduces inhibitory signaling whose efficiency is allele-dependent [PMID:30374408]. ADRB2 protein levels are set post-translationally: PHD3 binding destabilizes the receptor [PMID:28939592], while USP33-mediated deubiquitination stabilizes it and is antagonized by the hepatokine ERAP1 to interrupt insulin signaling in skeletal muscle [PMID:35192681]. ADRB2 expression is constrained transcriptionally by the repressor HIC1 [PMID:22194601] and by promoter-proximal SNPs that modulate NF1 and other nuclear-factor binding [PMID:23229733, PMID:29588580], post-transcriptionally by miR-15a-5p targeting its 3'UTR [PMID:31104300], and epigenetically by promoter hypermethylation [PMID:30986742]. In immune cells ADRB2 acts as an inhibitory checkpoint, restraining T/CAR-T cell function through a ZAP-70/NF-κB axis [PMID:39228124], while ADRB2+ interstitial macrophages near sympathetic nerves amplify norepinephrine-driven inflammation and lung injury [PMID:40466637]. In development and skeletal biology, β-cell ADRB2 restrains islet vascularization by suppressing VEGF-A [PMID:30303066] and mesenchymal-cell ADRB2 promotes osteoclastogenesis and bone remodeling [PMID:25252876, PMID:31926929].","teleology":[{"year":2010,"claim":"Established that whole-gene sequence variation in ADRB2 determines how much receptor reaches the cell surface and how it is downregulated by agonist, framing ADRB2 function as haplotype-dependent.","evidence":"Whole-gene haplotype transfection into COS-7 cells with radioligand binding and agonist-promoted downregulation assays","pmids":["20686604"],"confidence":"Medium","gaps":["Which individual polymorphisms drive the effect was not resolved","No link to downstream signaling consequences","Heterologous COS-7 system may not reflect native cell types"]},{"year":2011,"claim":"Identified HIC1 as a direct transcriptional repressor of ADRB2, explaining how loss of a tumor suppressor de-represses ADRB2 to drive cancer cell migration and invasion.","evidence":"Promoter luciferase, ChIP and sequential ChIP, siRNA knockdown, and migration/invasion rescue in breast cancer cells","pmids":["22194601"],"confidence":"High","gaps":["Downstream ADRB2 effectors mediating invasion not defined","Whether HIC1 acts at the same elements as functional SNPs unknown"]},{"year":2012,"claim":"Showed a promoter SNP reduces ADRB2 transcription and alters nuclear-factor binding, providing a functional basis for genetic association with obesity.","evidence":"Luciferase reporter comparing alleles and EMSA for nuclear factor binding","pmids":["23229733"],"confidence":"Medium","gaps":["Identity of the bound nuclear factor not determined","Causal link to obesity is associative, not mechanistic in vivo"]},{"year":2014,"claim":"Connected mechanical force to ADRB2 induction and bone resorption, showing Adrb2 raises the RANKL/OPG ratio to drive osteoclastogenesis.","evidence":"Compressive force on primary PDLCs, Ca2+ measurement, co-culture osteoclastogenesis, Adrb1/2 knockout mice, ganglionectomy","pmids":["25252876"],"confidence":"High","gaps":["Signaling between ADRB2 and RANKL induction not detailed","Cell-autonomy vs. neural contribution incompletely separated"]},{"year":2016,"claim":"Defined a mechanism by which ADRB2 suppresses autophagy—disrupting the Beclin1/VPS34/Atg14 complex via Akt—to stabilize HIF1α and confer therapy resistance.","evidence":"Reciprocal Co-IP, immunoblot, knockdown/inhibitor studies in HCC lines and xenografts","pmids":["27154061"],"confidence":"High","gaps":["How ADRB2 activates Akt in this context not resolved","Whether autophagy regulation generalizes beyond HCC unknown"]},{"year":2017,"claim":"Revealed post-translational control of ADRB2 by PHD3, showing that blocking PHD3-ADRB2 interaction stabilizes the receptor to counter muscle atrophy.","evidence":"Co-IP of PHD3-ADRB2, PHD3 inhibition/knockdown, AKG rescue in corticosterone and DMD atrophy models","pmids":["28939592"],"confidence":"Medium","gaps":["Whether PHD3 hydroxylates ADRB2 directly not established","Single lab; reciprocal validation limited"]},{"year":2018,"claim":"Demonstrated developmental, sex-specific roles for β-cell ADRB2 in restraining islet vascularization through VEGF-A suppression, linking receptor loss to glucose intolerance.","evidence":"Pancreas-specific conditional Adrb2 knockout, glucose/insulin assays, VEGF-A measurement, VEGFR-blockade rescue","pmids":["30303066"],"confidence":"High","gaps":["Basis of the female-specific phenotype unexplained","Signaling linking ADRB2 to VEGF-A repression undefined"]},{"year":2018,"claim":"Linked the ADRB2 Gly16/Arg16 polymorphism to Gi-coupling efficiency and β-blocker responsiveness, establishing a genotype-dependent signaling determinant of therapy.","evidence":"In vitro Gi-coupling assays plus genotype-stratified multicenter heart-failure cohorts","pmids":["30374408"],"confidence":"Medium","gaps":["Single mechanistic in vitro assay underpinning the clinical correlation","Molecular basis of altered Gi coupling not structurally resolved"]},{"year":2018,"claim":"Showed an upstream SNP alters NF1 binding and ADRB2 promoter activity, providing an allele-specific transcriptional mechanism tied to COPD susceptibility.","evidence":"Luciferase reporter, ChIP for NF1 binding, and ADRB2 expression in COPD patients","pmids":["29588580"],"confidence":"Medium","gaps":["Causal contribution to COPD pathophysiology not demonstrated","Whether NF1 regulation interacts with other repressors unknown"]},{"year":2018,"claim":"Identified ADRB2/VEGFR2 cross-talk and a CREB/PSAT1 axis as a driver of resistance to VEGFR2-TKIs in lung cancer, nominating ADRB2 blockade as a sensitizer.","evidence":"Co-IP of ADRB2/VEGFR2, propranolol treatment, CREB/PSAT1 analysis in NSCLC cells and xenografts","pmids":["35075132"],"confidence":"Medium","gaps":["Direct vs. indirect nature of ADRB2/VEGFR2 interaction unresolved","Single lab characterization"]},{"year":2019,"claim":"Mapped the transcriptional output of cancer-cell ADRB2 activation to an ERK1/2-JNK-MAPK cascade engaging NF-κB, AP-1, CREB and STAT3, with receptor-subtype specificity.","evidence":"Subtype-specific pharmacology (ICI118,551 vs. atenolol), pathway analysis, xenograft stress model in gastric cancer","pmids":["31624248"],"confidence":"Medium","gaps":["Relative contribution of each transcription factor not dissected","Effects on normal gastric epithelium untested"]},{"year":2019,"claim":"Established miR-15a-5p as a direct repressor of ADRB2 via its 3'UTR, defining a post-transcriptional brake that limits airway inflammatory gene expression.","evidence":"Luciferase reporter with WT/mutant 3'UTR, biotin pull-down, siRNA knockdown, ELISA in nasal epithelial cells","pmids":["31104300"],"confidence":"Medium","gaps":["In vivo relevance of the miR-15a-5p/ADRB2 axis not tested","Whether miR-16 acts identically not shown here"]},{"year":2019,"claim":"Showed that environmental epigenetic silencing of ADRB2 by promoter hypermethylation impairs PI3K/Akt signaling and triggers cardiomyocyte apoptosis.","evidence":"Methylation chip/BSP, ADRB2 overexpression, LY294002 inhibition, TUNEL, rat instillation model","pmids":["30986742"],"confidence":"Medium","gaps":["Enzymes driving the hypermethylation not identified","Single lab"]},{"year":2020,"claim":"Demonstrated that mesenchymal-cell ADRB2 promotes subchondral bone remodeling and osteoclastogenesis in joint osteoarthritis, extending its skeletal role to MSCs.","evidence":"Nestin-Cre x Adrb2 flox conditional knockout, crossbite model, histomorphometry and osteoclast quantification","pmids":["31926929"],"confidence":"High","gaps":["Pro-osteoclastic mediators downstream of MSC ADRB2 not fully defined","Relationship to RANKL/OPG mechanism from PDLCs not directly linked"]},{"year":2022,"claim":"Identified the hepatokine ERAP1 and the deubiquitinase USP33 as opposing regulators of ADRB2 protein stability that gate insulin signaling in muscle.","evidence":"Reciprocal Co-IP of ERAP1-ADRB2, USP33 knockdown/overexpression, hepatic ERAP1 manipulation, insulin-sensitivity assays","pmids":["35192681"],"confidence":"High","gaps":["Ubiquitin ligase opposing USP33 not identified","Site of ADRB2 ubiquitination unmapped"]},{"year":2022,"claim":"Linked ADRB2/PKA/CREB signaling to PPARγ-driven lipid synthesis, defining a role in glandular lipid production.","evidence":"Agonist/antagonist pharmacology, CREB phosphorylation and PPARγ/SREBP-1 readouts, lipid staining in meibomian gland cells","pmids":["36012741"],"confidence":"Medium","gaps":["Whether CREB directly drives PPARγ transcription not shown","Single cell-type, single lab"]},{"year":2023,"claim":"Showed ADRB2 promotes fibroblast-to-myofibroblast differentiation by stabilizing SMAD2/3, with inhibition attenuating lung fibrosis.","evidence":"ADRB2 gain/loss in lung fibroblasts, pSMAD2/3 immunoblot, proteasome inhibition, bleomycin mouse model","pmids":["37923730"],"confidence":"Medium","gaps":["How ADRB2 controls SMAD2/3 proteasomal degradation mechanistically unclear","Single lab"]},{"year":2023,"claim":"Found that ADRB2 activation by exercise can restore autophagy-lysosomal function via VMA21/V-ATPase to reduce amyloid pathology, an autophagy-promoting role contrasting its HCC autophagy-suppressing role.","evidence":"Exercise intervention and propranolol blockade in APP-PSEN1 mice, AMPK-mTOR/VMA21 analysis, amyloid and cognition readouts","pmids":["37964627"],"confidence":"Medium","gaps":["Reconciliation with autophagy-suppressing role in cancer unresolved","Direct link from ADRB2 to VMA21 not mechanistically dissected"]},{"year":2024,"claim":"Defined ADRB2 as an inhibitory checkpoint on CAR-T cells acting through a ZAP-70/NF-κB axis, nominating its knockdown to enhance anti-tumor T-cell function.","evidence":"RNAi knockdown in CAR-T cells, cytotoxicity and activation/exhaustion marker profiling, ZAP-70/NF-κB analysis, prostate cancer xenografts","pmids":["39228124"],"confidence":"Medium","gaps":["How ADRB2 couples to ZAP-70 not resolved","Endogenous catecholamine source in tumor not addressed"]},{"year":2025,"claim":"Placed ADRB2 in a neuroimmune circuit, showing ADRB2+ interstitial macrophages sense sympathetic norepinephrine to amplify lung inflammation during pneumonia.","evidence":"Opto/chemogenetic neural-circuit manipulation, norepinephrine measurement, ADRB2+ macrophage functional characterization, lethal pneumonia model","pmids":["40466637"],"confidence":"High","gaps":["Intracellular signaling from ADRB2 to cytokine output in macrophages not detailed","Generalizability beyond severe pneumonia unknown"]},{"year":null,"claim":"How ADRB2 signaling is rerouted to opposite outcomes in different cell types—autophagy suppression vs. promotion, pro- vs. anti-inflammatory effects—remains unresolved at the level of cell-type-specific effector wiring.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying account of context-dependent G-protein/effector coupling","Structural basis for allele- and cell-type-specific signaling unmapped","Endogenous ligand source and concentration in each tissue often inferred rather than measured"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,11,13]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[19,15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,11,13]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[0,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19,15]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,6]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,17,18]}],"complexes":[],"partners":["PHD3","USP33","ERAP1","VEGFR2","HIC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P07550","full_name":"Beta-2 adrenergic receptor","aliases":["Beta-2 adrenoreceptor","Beta-2 adrenoceptor"],"length_aa":413,"mass_kda":46.5,"function":"G protein-coupled receptor for catecholamines that couples to both G(s) and G(i) proteins, activating bifurcated signaling pathways (PubMed:2831218, PubMed:7915137). ADRB2 binds epinephrine (Epi) with an approximately 30-fold greater affinity than norepinephrine (NE) (PubMed:2831218, PubMed:33093660, PubMed:7915137). In the heart, Epi- and NE-activated ADRB2 induces rapid and slow cardiomyocyte contraction rate, respectively (By similarity). Both NE and Epi promote coupling to G(s)/PKA pathway to regulate myocyte contraction rate (By similarity). Epi also promotes ADRB2 coupling to G(i) proteins to exert cardioprotective effects especially in the conditions of hypoxia and oxidative stress through the G(i)/PI3K/Akt signaling pathway (By similarity). ADRB2-G(s) signaling delivers proapoptotic signals in cardiomyocytes although G(i)-mediated survival effect appears to predominate (By similarity). ADRB2 also transduces signals independently of PKA to regulate cellular pH by modulating Na(+)/H(+) exchanger SLC9A3 function (PubMed:9560162)","subcellular_location":"Cell membrane; Golgi apparatus","url":"https://www.uniprot.org/uniprotkb/P07550/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADRB2","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADRB2","total_profiled":1310},"omim":[{"mim_id":"619894","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 15; ABHD15","url":"https://www.omim.org/entry/619894"},{"mim_id":"619788","title":"ARRESTIN DOMAIN-CONTAINING PROTEIN 4; ARRDC4","url":"https://www.omim.org/entry/619788"},{"mim_id":"619490","title":"LMBR1 DOMAIN-CONTAINING PROTEIN 2; LMBRD2","url":"https://www.omim.org/entry/619490"},{"mim_id":"617483","title":"CORNICHON FAMILY AMPA RECEPTOR AUXILIARY PROTEIN 4; CNIH4","url":"https://www.omim.org/entry/617483"},{"mim_id":"615410","title":"MELANOCORTIN 2 RECEPTOR ACCESSORY PROTEIN 2; MRAP2","url":"https://www.omim.org/entry/615410"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Microtubules","reliability":"Additional"},{"location":"Cytokinetic bridge","reliability":"Additional"},{"location":"Mitotic spindle","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"breast","ntpm":32.4},{"tissue":"skin 1","ntpm":36.9}],"url":"https://www.proteinatlas.org/search/ADRB2"},"hgnc":{"alias_symbol":["ADRBR","BAR","B2AR","ARB2"],"prev_symbol":["ADRB2R"]},"alphafold":{"accession":"P07550","domains":[{"cath_id":"1.20.1070.10","chopping":"30-243_262-339","consensus_level":"medium","plddt":93.1239,"start":30,"end":339}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P07550","model_url":"https://alphafold.ebi.ac.uk/files/AF-P07550-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P07550-F1-predicted_aligned_error_v6.png","plddt_mean":79.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADRB2","jax_strain_url":"https://www.jax.org/strain/search?query=ADRB2"},"sequence":{"accession":"P07550","fasta_url":"https://rest.uniprot.org/uniprotkb/P07550.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P07550/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P07550"}},"corpus_meta":[{"pmid":"31624248","id":"PMC_31624248","title":"Chronic stress promotes gastric cancer progression and metastasis: an essential role for ADRB2.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31624248","citation_count":200,"is_preprint":false},{"pmid":"27154061","id":"PMC_27154061","title":"ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.","date":"2016","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/27154061","citation_count":199,"is_preprint":false},{"pmid":"18156033","id":"PMC_18156033","title":"Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.","date":"2007","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18156033","citation_count":167,"is_preprint":false},{"pmid":"9847294","id":"PMC_9847294","title":"Association of persistent bronchial hyperresponsiveness with beta2-adrenoceptor (ADRB2) haplotypes. A population study.","date":"1998","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9847294","citation_count":101,"is_preprint":false},{"pmid":"24621682","id":"PMC_24621682","title":"Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study.","date":"2014","source":"The Lancet. Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24621682","citation_count":82,"is_preprint":false},{"pmid":"30986742","id":"PMC_30986742","title":"PM2.5-induced ADRB2 hypermethylation contributed to cardiac dysfunction through cardiomyocytes apoptosis via PI3K/Akt pathway.","date":"2019","source":"Environment international","url":"https://pubmed.ncbi.nlm.nih.gov/30986742","citation_count":71,"is_preprint":false},{"pmid":"15596681","id":"PMC_15596681","title":"Polymorphisms of IL4, IL13, and ADRB2 genes in COPD.","date":"2004","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/15596681","citation_count":71,"is_preprint":false},{"pmid":"25162199","id":"PMC_25162199","title":"Interaction of the ADRB2 gene polymorphism with childhood trauma in predicting adult symptoms of posttraumatic stress disorder.","date":"2014","source":"JAMA psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/25162199","citation_count":70,"is_preprint":false},{"pmid":"25252876","id":"PMC_25252876","title":"Force-induced Adrb2 in periodontal ligament cells promotes tooth movement.","date":"2014","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/25252876","citation_count":64,"is_preprint":false},{"pmid":"11821707","id":"PMC_11821707","title":"Polymorphisms of the beta2 -adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies.","date":"2002","source":"Journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/11821707","citation_count":58,"is_preprint":false},{"pmid":"10971791","id":"PMC_10971791","title":"Polymorphisms of the beta2-adrenergic receptor gene (ADRB2) in relation to cardiovascular risk factors in men.","date":"2000","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10971791","citation_count":48,"is_preprint":false},{"pmid":"22862293","id":"PMC_22862293","title":"An environmental epigenetic study of ADRB2 5'-UTR methylation and childhood asthma severity.","date":"2012","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22862293","citation_count":47,"is_preprint":false},{"pmid":"19905915","id":"PMC_19905915","title":"Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis.","date":"2009","source":"The Journal of asthma : official journal of the Association for the Care of Asthma","url":"https://pubmed.ncbi.nlm.nih.gov/19905915","citation_count":46,"is_preprint":false},{"pmid":"28939592","id":"PMC_28939592","title":"α-Ketoglutarate prevents skeletal muscle protein degradation and muscle atrophy through PHD3/ADRB2 pathway.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28939592","citation_count":45,"is_preprint":false},{"pmid":"21545619","id":"PMC_21545619","title":"Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy.","date":"2010","source":"Journal of clinical pharmacy and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/21545619","citation_count":44,"is_preprint":false},{"pmid":"18611262","id":"PMC_18611262","title":"Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II.","date":"2008","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/18611262","citation_count":43,"is_preprint":false},{"pmid":"24461901","id":"PMC_24461901","title":"Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.","date":"2013","source":"The Lancet. Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24461901","citation_count":38,"is_preprint":false},{"pmid":"20686604","id":"PMC_20686604","title":"Common ADRB2 haplotypes derived from 26 polymorphic sites direct beta2-adrenergic receptor expression and regulation phenotypes.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20686604","citation_count":36,"is_preprint":false},{"pmid":"30871232","id":"PMC_30871232","title":"ADRB2-Targeting Therapies for Prostate Cancer.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/30871232","citation_count":34,"is_preprint":false},{"pmid":"15153795","id":"PMC_15153795","title":"ADRB2 polymorphisms and asthma susceptibility: transmission disequilibrium test and meta-analysis.","date":"2004","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15153795","citation_count":32,"is_preprint":false},{"pmid":"17130852","id":"PMC_17130852","title":"Association of a beta-2 adrenoceptor (ADRB2) gene variant with a blunted in vivo lipolysis and fat oxidation.","date":"2006","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/17130852","citation_count":31,"is_preprint":false},{"pmid":"22950544","id":"PMC_22950544","title":"Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis.","date":"2012","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22950544","citation_count":30,"is_preprint":false},{"pmid":"18758858","id":"PMC_18758858","title":"Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease.","date":"2008","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/18758858","citation_count":30,"is_preprint":false},{"pmid":"30542705","id":"PMC_30542705","title":"β‑blockers inhibit the viability of breast cancer cells by regulating the ERK/COX‑2 signaling pathway and the drug response is affected by ADRB2 single‑nucleotide polymorphisms.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/30542705","citation_count":29,"is_preprint":false},{"pmid":"22937051","id":"PMC_22937051","title":"Human-specific SNP in obesity genes, adrenergic receptor beta2 (ADRB2), Beta3 (ADRB3), and PPAR γ2 (PPARG), during primate evolution.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22937051","citation_count":28,"is_preprint":false},{"pmid":"37964627","id":"PMC_37964627","title":"Aerobic exercise attenuates autophagy-lysosomal flux deficits by ADRB2/β2-adrenergic receptor-mediated V-ATPase assembly factor VMA21 signaling in APP-PSEN1/PS1 mice.","date":"2023","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/37964627","citation_count":27,"is_preprint":false},{"pmid":"32194709","id":"PMC_32194709","title":"HSP90AA1, ADRB2, TBL1XR1 and HSPB1 are chronic obstructive pulmonary disease-related genes that facilitate squamous cell lung cancer progression.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/32194709","citation_count":27,"is_preprint":false},{"pmid":"31926929","id":"PMC_31926929","title":"Conditional deletion of Adrb2 in mesenchymal stem cells attenuates osteoarthritis-like defects in temporomandibular joint.","date":"2020","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/31926929","citation_count":27,"is_preprint":false},{"pmid":"23911093","id":"PMC_23911093","title":"Association of the FTO and ADRB2 genes with body composition and fat distribution in obese women.","date":"2013","source":"Maturitas","url":"https://pubmed.ncbi.nlm.nih.gov/23911093","citation_count":27,"is_preprint":false},{"pmid":"29331538","id":"PMC_29331538","title":"Differential lipid metabolism outcomes associated with ADRB2 gene polymorphisms in response to two dietary interventions in overweight/obese subjects.","date":"2017","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/29331538","citation_count":27,"is_preprint":false},{"pmid":"22194601","id":"PMC_22194601","title":"Loss of Hypermethylated in Cancer 1 (HIC1) in breast cancer cells contributes to stress-induced migration and invasion through β-2 adrenergic receptor (ADRB2) misregulation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22194601","citation_count":27,"is_preprint":false},{"pmid":"18625943","id":"PMC_18625943","title":"Intraocular pressure response to topical beta-blockers associated with an ADRB2 single-nucleotide polymorphism.","date":"2008","source":"Archives of ophthalmology (Chicago, Ill. : 1960)","url":"https://pubmed.ncbi.nlm.nih.gov/18625943","citation_count":27,"is_preprint":false},{"pmid":"35645356","id":"PMC_35645356","title":"Cardamonin suppressed the migration, invasion, epithelial mesenchymal transition (EMT) and lung metastasis of colorectal cancer cells by down-regulating ADRB2 expression.","date":"2022","source":"Pharmaceutical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35645356","citation_count":26,"is_preprint":false},{"pmid":"30303066","id":"PMC_30303066","title":"Adrb2 controls glucose homeostasis by developmental regulation of pancreatic islet vasculature.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30303066","citation_count":26,"is_preprint":false},{"pmid":"25111792","id":"PMC_25111792","title":"Beta-2 adrenergic receptor (ADRB2) gene polymorphisms and the risk of asthma: a meta-analysis of case-control studies.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25111792","citation_count":25,"is_preprint":false},{"pmid":"17075257","id":"PMC_17075257","title":"Molecular-based haplotype analysis of the beta 2-adrenergic receptor gene (ADRB2) in Japanese asthmatic and non-asthmatic subjects.","date":"2006","source":"Allergology international : official journal of the Japanese Society of Allergology","url":"https://pubmed.ncbi.nlm.nih.gov/17075257","citation_count":25,"is_preprint":false},{"pmid":"30374408","id":"PMC_30374408","title":"ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure.","date":"2018","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/30374408","citation_count":25,"is_preprint":false},{"pmid":"31104300","id":"PMC_31104300","title":"ADRB2 suppresses IL-13-induced allergic rhinitis inflammatory cytokine regulated by miR-15a-5p.","date":"2019","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/31104300","citation_count":24,"is_preprint":false},{"pmid":"22383665","id":"PMC_22383665","title":"ADRB2 polymorphisms and budesonide/formoterol responses in COPD.","date":"2012","source":"Chest","url":"https://pubmed.ncbi.nlm.nih.gov/22383665","citation_count":24,"is_preprint":false},{"pmid":"21436355","id":"PMC_21436355","title":"ADRB2 Gly16Arg polymorphism, asthma control and lung function decline.","date":"2011","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/21436355","citation_count":24,"is_preprint":false},{"pmid":"18789663","id":"PMC_18789663","title":"CT scanning-based phenotypes vary with ADRB2 polymorphisms in chronic obstructive pulmonary disease.","date":"2008","source":"Respiratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18789663","citation_count":24,"is_preprint":false},{"pmid":"37489008","id":"PMC_37489008","title":"Saikosaponin D reverses epinephrine- and norepinephrine-induced gemcitabine resistance in intrahepatic cholangiocarcinoma by downregulating ADRB2/glycolysis signaling.","date":"2023","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/37489008","citation_count":23,"is_preprint":false},{"pmid":"16289313","id":"PMC_16289313","title":"Beta-2 adrenergic receptor gene (ADRB2) polymorphism and risk for lung adenocarcinoma: a case-control study in a Chinese population.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16289313","citation_count":23,"is_preprint":false},{"pmid":"39228124","id":"PMC_39228124","title":"Intrinsic ADRB2 inhibition improves CAR-T cell therapy efficacy against prostate cancer.","date":"2024","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/39228124","citation_count":20,"is_preprint":false},{"pmid":"26613553","id":"PMC_26613553","title":"Four-locus gene interaction between IL13, IL4, FCER1B, and ADRB2 for asthma in Chinese Han children.","date":"2015","source":"Pediatric pulmonology","url":"https://pubmed.ncbi.nlm.nih.gov/26613553","citation_count":20,"is_preprint":false},{"pmid":"23786226","id":"PMC_23786226","title":"Genetic variation in the beta-2 adrenergic receptor (ADRB2) predicts functional gastrointestinal diagnoses and poorer health-related quality of life.","date":"2013","source":"Alimentary pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23786226","citation_count":20,"is_preprint":false},{"pmid":"40466637","id":"PMC_40466637","title":"A brain-to-lung signal from GABAergic neurons to ADRB2+ interstitial macrophages promotes pulmonary inflammatory responses.","date":"2025","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/40466637","citation_count":19,"is_preprint":false},{"pmid":"20230274","id":"PMC_20230274","title":"Polymorphisms in the ACE and ADRB2 genes and risks of aging-associated phenotypes: the case of myocardial infarction.","date":"2010","source":"Rejuvenation research","url":"https://pubmed.ncbi.nlm.nih.gov/20230274","citation_count":19,"is_preprint":false},{"pmid":"24688286","id":"PMC_24688286","title":"Obesity-related gene ADRB2, ADRB3 and GHRL polymorphisms and the response to a weight loss diet intervention in adult women.","date":"2013","source":"Genetics and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24688286","citation_count":19,"is_preprint":false},{"pmid":"31007954","id":"PMC_31007954","title":"Association of ADRB2 rs1042713 with Obesity and Obesity-Related Phenotypes and Its Interaction with Dietary Fat in Modulating Glycaemic Indices in Malaysian Adults.","date":"2019","source":"Journal of nutrition and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31007954","citation_count":19,"is_preprint":false},{"pmid":"20829805","id":"PMC_20829805","title":"ADRB2 haplotype is associated with glucose tolerance and insulin sensitivity in obese postmenopausal women.","date":"2010","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20829805","citation_count":19,"is_preprint":false},{"pmid":"33675465","id":"PMC_33675465","title":"The role of ADRB2 gene polymorphisms in malignancies.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33675465","citation_count":18,"is_preprint":false},{"pmid":"35075132","id":"PMC_35075132","title":"Targeting ADRB2 enhances sensitivity of non-small cell lung cancer to VEGFR2 tyrosine kinase inhibitors.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35075132","citation_count":18,"is_preprint":false},{"pmid":"25824473","id":"PMC_25824473","title":"Expression of the beta-2 adrenergic receptor (ADRB-2) in human and monkey ovarian follicles: a marker of growing follicles?","date":"2015","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/25824473","citation_count":18,"is_preprint":false},{"pmid":"12442282","id":"PMC_12442282","title":"Determination of beta2-adrenergic receptor (ADRB2) haplotypes by a multiplexed polymerase chain reaction assay.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12442282","citation_count":18,"is_preprint":false},{"pmid":"16493638","id":"PMC_16493638","title":"Impact of variation in ADRB2, ADRB3, and GNB3 genes on body mass index and waist circumference in a Brazilian population.","date":"2006","source":"American journal of human biology : the official journal of the Human Biology Council","url":"https://pubmed.ncbi.nlm.nih.gov/16493638","citation_count":18,"is_preprint":false},{"pmid":"28506092","id":"PMC_28506092","title":"Variants of the ADRB2 Gene in COPD: Systematic Review and Meta-Analyses of Disease Risk and Treatment Response.","date":"2017","source":"COPD","url":"https://pubmed.ncbi.nlm.nih.gov/28506092","citation_count":17,"is_preprint":false},{"pmid":"35192681","id":"PMC_35192681","title":"Hepatokine ERAP1 Disturbs Skeletal Muscle Insulin Sensitivity Via Inhibiting USP33-Mediated ADRB2 Deubiquitination.","date":"2022","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/35192681","citation_count":17,"is_preprint":false},{"pmid":"31285095","id":"PMC_31285095","title":"Evaluation of genetic risk related to catechol-O-methyltransferase (COMT) and β2-adrenergic receptor (ADRB2) activity in different diagnostic subgroups of temporomandibular disorder in Brazilian patients.","date":"2019","source":"International journal of oral and maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/31285095","citation_count":17,"is_preprint":false},{"pmid":"19747908","id":"PMC_19747908","title":"Development of novel microarray methodology for the study of mutations in the SERPINA1 and ADRB2 genes--their association with Obstructive Pulmonary Disease and Disseminated Bronchiectasis in Greek patients.","date":"2009","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19747908","citation_count":17,"is_preprint":false},{"pmid":"21233812","id":"PMC_21233812","title":"ADRB2 and LEPR gene polymorphisms: synergistic effects on the risk of obesity in Japanese.","date":"2011","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21233812","citation_count":16,"is_preprint":false},{"pmid":"37923730","id":"PMC_37923730","title":"ADRB2 inhibition combined with antioxidant treatment alleviates lung fibrosis by attenuating TGFβ/SMAD signaling in lung fibroblasts.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37923730","citation_count":16,"is_preprint":false},{"pmid":"24012958","id":"PMC_24012958","title":"Single nucleotide polymorphisms of ADRB2 gene and their association with susceptibility for Plasmodium falciparum malaria and asthma in an Indian population.","date":"2013","source":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24012958","citation_count":16,"is_preprint":false},{"pmid":"19779622","id":"PMC_19779622","title":"No consistent effect of ADRB2 haplotypes on obesity, hypertension and quantitative traits of body fatness and blood pressure among 6,514 adult Danes.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19779622","citation_count":16,"is_preprint":false},{"pmid":"30942450","id":"PMC_30942450","title":"Upregulation of microRNA‑16 alters the response to inhaled β‑agonists in patients with asthma though modulating expression of ADRB2.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30942450","citation_count":16,"is_preprint":false},{"pmid":"19284637","id":"PMC_19284637","title":"Polymorphisms in the ADRB2 gene and Graves disease: a case-control study and a meta-analysis of available evidence.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19284637","citation_count":15,"is_preprint":false},{"pmid":"20739939","id":"PMC_20739939","title":"A46G and C79G polymorphisms in the β2-adrenergic receptor gene (ADRB2) and essential hypertension risk: a meta-analysis.","date":"2010","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/20739939","citation_count":15,"is_preprint":false},{"pmid":"31685439","id":"PMC_31685439","title":"Association between ADRB2, IL33, and IL2RB gene polymorphisms and lung cancer risk in a Chinese Han population.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31685439","citation_count":15,"is_preprint":false},{"pmid":"31264537","id":"PMC_31264537","title":"Polymorphisms in COMT, ADRB2 and HTR1A genes are associated with temporomandibular disorders in individuals with other arthralgias.","date":"2019","source":"Cranio : the journal of craniomandibular practice","url":"https://pubmed.ncbi.nlm.nih.gov/31264537","citation_count":15,"is_preprint":false},{"pmid":"36163241","id":"PMC_36163241","title":"ADRB2 expression predicts the clinical outcomes and is associated with immune cells infiltration in lung adenocarcinoma.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36163241","citation_count":14,"is_preprint":false},{"pmid":"31683975","id":"PMC_31683975","title":"β2-Adrenergic Receptor (ADRB2) Gene Polymorphisms and Risk of COPD Exacerbations: The Rotterdam Study.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31683975","citation_count":14,"is_preprint":false},{"pmid":"36012741","id":"PMC_36012741","title":"Activation of ADRB2/PKA Signaling Pathway Facilitates Lipid Synthesis in Meibocytes, and Beta-Blocker Glaucoma Drug Impedes PKA-Induced Lipid Synthesis by Inhibiting ADRB2.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012741","citation_count":14,"is_preprint":false},{"pmid":"35116377","id":"PMC_35116377","title":"ADRB2 is a potential protective gene in breast cancer by regulating tumor immune microenvironment.","date":"2021","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35116377","citation_count":14,"is_preprint":false},{"pmid":"22731644","id":"PMC_22731644","title":"CYP2J2 -50 G/T and ADRB2 G46A gene polymorphisms in Saudi subjects with hypertension.","date":"2012","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/22731644","citation_count":14,"is_preprint":false},{"pmid":"19086034","id":"PMC_19086034","title":"Characterization of a de novo translocation t(5;18)(q33.1;q12.1) in an autistic boy identifies a breakpoint close to SH3TC2, ADRB2, and HTR4 on 5q, and within the desmocollin gene cluster on 18q.","date":"2009","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19086034","citation_count":14,"is_preprint":false},{"pmid":"22559839","id":"PMC_22559839","title":"Effect of β2-adrenergic receptor gene (ADRB2) 3' untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist response.","date":"2012","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/22559839","citation_count":14,"is_preprint":false},{"pmid":"29588580","id":"PMC_29588580","title":"A functional SNP upstream of the ADRB2 gene is associated with COPD.","date":"2018","source":"International journal of chronic obstructive pulmonary disease","url":"https://pubmed.ncbi.nlm.nih.gov/29588580","citation_count":13,"is_preprint":false},{"pmid":"30855197","id":"PMC_30855197","title":"Role of THRB, ARG1, and ADRB2 Genetic Variants on Bronchodilators Response in Asthmatic Children.","date":"2019","source":"Journal of aerosol medicine and pulmonary drug delivery","url":"https://pubmed.ncbi.nlm.nih.gov/30855197","citation_count":13,"is_preprint":false},{"pmid":"26888112","id":"PMC_26888112","title":"Influence of ADRB2 Gln27Glu and ADRB3 Trp64Arg polymorphisms on body weight and body composition changes after a controlled weight-loss intervention.","date":"2015","source":"Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/26888112","citation_count":13,"is_preprint":false},{"pmid":"19638684","id":"PMC_19638684","title":"Role of ADRB2 gene polymorphism in asthma and response to beta(2)-agonists in Polish children.","date":"2009","source":"Journal of applied genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19638684","citation_count":13,"is_preprint":false},{"pmid":"25985706","id":"PMC_25985706","title":"Effect of ADRB2 (adrenergic receptor β2) gene polymorphisms on the occurrence of asthma and on the response to nebulized salbutamol in South Indian patients with bronchial asthma.","date":"2015","source":"The Journal of asthma : official journal of the Association for the Care of Asthma","url":"https://pubmed.ncbi.nlm.nih.gov/25985706","citation_count":13,"is_preprint":false},{"pmid":"39080269","id":"PMC_39080269","title":"CRISPR-CasRx-mediated disruption of Aqp1/Adrb2/Rock1/Rock2 genes reduces intraocular pressure and retinal ganglion cell damage in mice.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39080269","citation_count":12,"is_preprint":false},{"pmid":"22158330","id":"PMC_22158330","title":"A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients.","date":"2011","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/22158330","citation_count":12,"is_preprint":false},{"pmid":"26111150","id":"PMC_26111150","title":"Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension.","date":"2015","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/26111150","citation_count":12,"is_preprint":false},{"pmid":"25233048","id":"PMC_25233048","title":"SPINK5 and ADRB2 haplotypes are risk factors for asthma in Mexican pediatric patients.","date":"2014","source":"The Journal of asthma : official journal of the Association for the Care of Asthma","url":"https://pubmed.ncbi.nlm.nih.gov/25233048","citation_count":12,"is_preprint":false},{"pmid":"17356698","id":"PMC_17356698","title":"ADRB2 Arg16Gly polymorphism, lung function, and mortality: results from the Atherosclerosis Risk in Communities study.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17356698","citation_count":12,"is_preprint":false},{"pmid":"16082424","id":"PMC_16082424","title":"Polymorphic variants of the beta2-adrenergic receptor (ADRB2) gene and ADRB2-related propanolol-induced dyslipidemia in the Colombian population.","date":"2005","source":"Methods and findings in experimental and clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16082424","citation_count":11,"is_preprint":false},{"pmid":"16554384","id":"PMC_16554384","title":"Anger suppression and adiposity modulate association between ADRB2 haplotype and cardiovascular stress reactivity.","date":"2006","source":"Psychosomatic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16554384","citation_count":11,"is_preprint":false},{"pmid":"26692153","id":"PMC_26692153","title":"ADRB2 polymorphisms predict the risk of myocardial infarction and coronary artery disease.","date":"2015","source":"Genetics and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26692153","citation_count":11,"is_preprint":false},{"pmid":"35268025","id":"PMC_35268025","title":"FTO and ADRB2 Genetic Polymorphisms Are Risk Factors for Earlier Excessive Gestational Weight Gain in Pregnant Women with Pregestational Diabetes Mellitus: Results of a Randomized Nutrigenetic Trial.","date":"2022","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/35268025","citation_count":11,"is_preprint":false},{"pmid":"22864926","id":"PMC_22864926","title":"ADRB2 G-G haplotype associated with breast cancer risk among Hispanic and non-Hispanic white women: interaction with type 2 diabetes and obesity.","date":"2012","source":"Cancer causes & control : CCC","url":"https://pubmed.ncbi.nlm.nih.gov/22864926","citation_count":11,"is_preprint":false},{"pmid":"17243909","id":"PMC_17243909","title":"Association between polymorphisms of ACE, B2AR, ANP and ENOS and cardiovascular diseases: a community-based study in the Matsu area.","date":"2007","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17243909","citation_count":10,"is_preprint":false},{"pmid":"36712945","id":"PMC_36712945","title":"10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling.","date":"2023","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36712945","citation_count":10,"is_preprint":false},{"pmid":"11956670","id":"PMC_11956670","title":"Allele and genotype frequencies of polymorphic DCP1, CETP, ADRB2, and HTR2A in the Egyptian population.","date":"2002","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11956670","citation_count":10,"is_preprint":false},{"pmid":"32101872","id":"PMC_32101872","title":"The Combined Effect of Polygenic Risk from FTO and ADRB2 Gene Variants, Odds of Obesity, and Post-Hipcref Diet Differences.","date":"2020","source":"Lifestyle genomics","url":"https://pubmed.ncbi.nlm.nih.gov/32101872","citation_count":10,"is_preprint":false},{"pmid":"23229733","id":"PMC_23229733","title":"A functional SNP upstream of the beta-2 adrenergic receptor gene (ADRB2) is associated with obesity in Oceanic populations.","date":"2012","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/23229733","citation_count":10,"is_preprint":false},{"pmid":"24016068","id":"PMC_24016068","title":"Interactions between social/ behavioral factors and ADRB2 genotypes may be associated with health at advanced ages in China.","date":"2013","source":"BMC geriatrics","url":"https://pubmed.ncbi.nlm.nih.gov/24016068","citation_count":10,"is_preprint":false},{"pmid":"34128573","id":"PMC_34128573","title":"ADRB2 haplotypes and asthma exacerbations in children and young adults: An individual participant data meta-analysis.","date":"2021","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34128573","citation_count":9,"is_preprint":false},{"pmid":"38841722","id":"PMC_38841722","title":"Genetic variants in DBC1, SIRT1, UCP2 and ADRB2 as potential biomarkers for severe obesity and metabolic complications.","date":"2024","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38841722","citation_count":9,"is_preprint":false},{"pmid":"26633084","id":"PMC_26633084","title":"ADRB2 polymorphisms in allergic asthma in Han Chinese children.","date":"2015","source":"International forum of allergy & rhinology","url":"https://pubmed.ncbi.nlm.nih.gov/26633084","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":61755,"output_tokens":5757,"usd":0.13581,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14392,"output_tokens":6139,"usd":0.112717,"stage2_stop_reason":"end_turn"},"total_usd":0.248527,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"ADRB2 signaling negatively regulates autophagy by disrupting the Beclin1/VPS34/Atg14 complex in an Akt-dependent manner, leading to HIF1α stabilization through inhibition of autophagic degradation, reprogramming of HCC cell glucose metabolism, and acquisition of sorafenib resistance. Knockdown of ADRB2 enhanced autophagy and destabilized HIF1α.\",\n      \"method\": \"Immunoblotting, immunofluorescence, immunoprecipitation, knockdown/inhibitor studies in HCC cell lines and nude mouse xenografts\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP of Beclin1/VPS34/Atg14 complex disruption, multiple orthogonal methods (immunoprecipitation, immunoblot, in vivo xenograft, genetic knockdown and pharmacologic inhibition), replicated across cell lines and mouse model\",\n      \"pmids\": [\"27154061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HIC1 (Hypermethylated in Cancer 1) is a direct transcriptional repressor of ADRB2. Loss of HIC1 in breast cancer cells leads to upregulation of ADRB2, and agonist-mediated stimulation of ADRB2 increases migration and invasion of MDA-MB-231 cells; these effects are abolished by HIC1 re-expression or ADRB2 siRNA knockdown.\",\n      \"method\": \"Promoter luciferase assay, chromatin immunoprecipitation (ChIP), sequential ChIP, siRNA knockdown, migration/invasion assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP demonstrating HIC1 binding to ADRB2 promoter, luciferase reporter, sequential ChIP, functional rescue experiments with siRNA\",\n      \"pmids\": [\"22194601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Mechanical compressive force upregulates Adrb2 expression in human periodontal ligament cells (PDLCs) via elevation of intracellular Ca2+ concentration. Activation of Adrb2 in PDLCs increases the RANKL/OPG ratio and promotes peripheral blood mononuclear cell differentiation into osteoclasts, thereby facilitating bone resorption and orthodontic tooth movement.\",\n      \"method\": \"In vitro compressive force application to primary PDLCs, intracellular Ca2+ measurement, RANKL/OPG ratio assay, co-culture osteoclastogenesis assay, Adrb1/2 knockout mice, superior cervical ganglionectomy in rats\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout mice (Adrb1/2−/−), pharmacologic manipulation, mechanistic cell assays, and in vivo orthodontic model with multiple orthogonal methods\",\n      \"pmids\": [\"25252876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"α-Ketoglutarate (AKG) inhibits PHD3 expression and blocks PHD3-ADRB2 interaction, thereby increasing ADRB2 protein stability. AKG rescues skeletal muscle atrophy and protein degradation through this PHD3/ADRB2-mediated mechanism.\",\n      \"method\": \"Pharmacological and genetic approaches (PHD3 inhibition/knockdown), co-immunoprecipitation of PHD3-ADRB2, corticosterone-induced atrophy model, Duchenne muscular dystrophy mouse model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying PHD3-ADRB2 interaction, genetic and pharmacologic rescue in vivo, single lab with two orthogonal approaches\",\n      \"pmids\": [\"28939592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Pancreas-specific deletion of Adrb2 results in glucose intolerance and impaired insulin secretion specifically in female mice. Mechanistically, neonatal Adrb2 loss increases VEGF-A production in female neonatal β-cells, causing hyper-vascularized islets during development that disrupts insulin production and exocytosis. Neonatal VEGF-A receptor blockade fully rescues the glucose homeostasis deficits.\",\n      \"method\": \"Conditional knockout (nestin-Cre and pancreas-specific Cre x Adrb2 flox mice), glucose tolerance tests, insulin secretion assays, VEGF-A measurement, VEGFR blockade rescue experiments\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional knockout with multiple phenotypic readouts, mechanistic rescue by VEGFR blockade, sex-specific and developmental-stage-specific dissection\",\n      \"pmids\": [\"30303066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Conditional deletion of Adrb2 specifically in nestin+ mesenchymal stem cells attenuates subchondral bone loss and cartilage degradation in a temporomandibular joint osteoarthritis model, demonstrating that Adrb2 signaling in MSCs promotes osteoclastogenesis and subchondral bone remodeling.\",\n      \"method\": \"Nestin-Cre x Adrb2 flox conditional knockout mice, unilateral anterior crossbite model, histomorphometry, bone mineral density, osteoclast surface quantification, pro-osteoclastic factor expression\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional knockout with detailed quantitative histomorphometric phenotyping across multiple bone and cartilage parameters\",\n      \"pmids\": [\"31926929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ERAP1 (hepatokine endoplasmic reticulum aminopeptidase 1) physically interacts with ADRB2 and reduces ADRB2 protein expression by decreasing USP33 (ubiquitin-specific peptidase 33)-mediated deubiquitination, thereby interrupting ADRB2-stimulated insulin signaling in skeletal muscle.\",\n      \"method\": \"Co-immunoprecipitation of ERAP1-ADRB2 interaction, USP33 knockdown/overexpression, hepatic ERAP1 overexpression and knockdown in mice, insulin sensitivity assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP identifying ERAP1-ADRB2 interaction, deubiquitinase (USP33) identified as ADRB2 writer/eraser, in vivo genetic manipulation with functional metabolic readouts\",\n      \"pmids\": [\"35192681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ADRB2 haplotypes constructed from 26 polymorphisms across the entire intronless gene (promoter, 5'UTR, coding, 3'UTR) drive differential cell-surface β2AR protein expression and agonist-promoted downregulation in a haplotype-dependent manner when expressed in COS-7 cells.\",\n      \"method\": \"Whole-gene haplotype transfection into COS-7 cells, radioligand binding for cell-surface receptor quantification, agonist-promoted downregulation assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based transfection with quantitative receptor expression and downregulation assays, single lab, multiple haplotypes tested\",\n      \"pmids\": [\"20686604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Activation of the ADRB2/PKA signaling pathway enhances PPARγ expression and lipid synthesis in human meibomian gland epithelial cells (HMGECs). The ADRB2 agonist salbutamol increased PPARγ expression and lipid synthesis, while the ADRB2 antagonist timolol had the opposite effect, mediated through CREB phosphorylation.\",\n      \"method\": \"Pharmacological agonist/antagonist treatment of HMGECs, immunoblotting for CREB phosphorylation, PPARγ and SREBP-1 expression, LipidTOX staining, AdipoRed assay, Oil Red O staining\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacologic activation and inhibition of ADRB2 with multiple lipid synthesis readouts, single lab, two orthogonal methods\",\n      \"pmids\": [\"36012741\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Aerobic exercise activates ADRB2/β2-adrenergic receptor signaling, which reverses autophagy-lysosomal deficits by upregulating VMA21 levels to restore V-ATPase function, reducing amyloid-β pathology in APP-PSEN1 mice. Propranolol (ADRB2 antagonist) blocked these exercise-induced benefits.\",\n      \"method\": \"Aerobic exercise intervention in APP-PSEN1 transgenic mice, propranolol pharmacologic blockade, AMPK-mTOR pathway analysis, VMA21 expression, amyloid-β quantification, cognitive testing\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic/pharmacologic ADRB2 manipulation in transgenic disease model, pathway analysis with multiple molecular readouts, single lab\",\n      \"pmids\": [\"37964627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PM2.5 exposure causes ADRB2 promoter hypermethylation, reducing β2AR expression and inhibiting PI3K/Akt signaling, which activates Bcl-2/BAX and p53 apoptotic pathways in cardiomyocytes. ADRB2 overexpression attenuated PM2.5-induced apoptosis, an effect abolished by PI3K inhibitor LY294002.\",\n      \"method\": \"DNA methylation chip and bisulfite sequencing PCR (BSP) in AC16 cardiomyocytes, ADRB2 overexpression transgenic cell lines, PI3K inhibitor LY294002, TUNEL assay, rat intratracheal instillation model, echocardiography\",\n      \"journal\": \"Environment international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epigenetic mechanism (methylation) identified with BSP, functional rescue by ADRB2 overexpression and pathway inhibition, in vivo model corroboration, single lab\",\n      \"pmids\": [\"30986742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ADRB2 Gly16 allele carriers with heart failure show defective β2AR-coupled inhibitory Gi protein signaling in vitro, and Gly16 allele carriers show beneficial response to β-blocker therapy in a dose-dependent manner, whereas Arg16 homozygotes show no response.\",\n      \"method\": \"In vitro signaling assays for Gi coupling, multicenter cohort study (2403 + 919 patients), genotype-stratified analysis of clinical outcomes\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro Gi signaling experiment plus large independent clinical validation cohort, single mechanistic assay but replicated clinically\",\n      \"pmids\": [\"30374408\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ADRB2 signaling promotes resistance to VEGFR2-TKIs in non-small cell lung cancer via upregulation of ADRB2/VEGFR2 interaction and activation of the ADRB2/CREB/PSAT1 signaling pathway. Pharmacologic ADRB2 inhibition (propranolol) sensitized NSCLC cells to VEGFR2-TKIs in vitro and in vivo.\",\n      \"method\": \"Co-immunoprecipitation of ADRB2/VEGFR2 interaction, ADRB2 inhibitor (propranolol) treatment in NSCLC cell lines and xenograft models, CREB/PSAT1 pathway analysis\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for ADRB2/VEGFR2 interaction, pharmacologic and in vivo validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"35075132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ADRB2 activation by epinephrine/norepinephrine in gastric cancer cells promotes proliferation, invasion, and metastasis through the ERK1/2-JNK-MAPK pathway and transcription factors NF-κB, AP-1, CREB, and STAT3. ADRB2-specific antagonist ICI118,551 reversed these effects; ADRB1 antagonist atenolol had no effect.\",\n      \"method\": \"Proliferation, migration, invasion, cell cycle, and apoptosis assays in GC cell lines; ERK1/2-JNK-MAPK pathway analysis; xenograft mouse models with chronic restraint stress; ICI118,551 and atenolol pharmacologic discrimination\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-subtype-specific pharmacologic discrimination, multiple downstream pathway readouts, in vivo xenograft model, single lab\",\n      \"pmids\": [\"31624248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-15a-5p directly targets the ADRB2 3'UTR and reduces ADRB2 mRNA and protein expression in a dose-dependent manner. ADRB2 knockdown inhibited IL-13-induced expression of GM-CSF, eotaxin, and MUC5AC in nasal epithelial cells, and miR-15a-5p mediated its anti-inflammatory effect through ADRB2.\",\n      \"method\": \"Luciferase reporter assay (wild-type vs. mutant ADRB2 3'UTR), biotin pull-down assay, siRNA knockdown, ELISA, Western blotting in IL-13-stimulated human nasal epithelial cells\",\n      \"journal\": \"Human cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter with wild-type/mutant 3'UTR confirming direct miR-15a-5p targeting, functional knockdown rescue, single lab\",\n      \"pmids\": [\"31104300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A subpopulation of ADRB2+ interstitial macrophages surrounding pulmonary sympathetic nerves responds to norepinephrine released via a CeA-RVLM-sympathetic neural pathway, amplifying inflammatory cytokine production and lung injury during severe pneumonia. Specific inhibition of pulmonary sympathetic nerves or ADRB2 signaling improved outcomes.\",\n      \"method\": \"Optogenetic/chemogenetic inhibition of CeA GABAergic neurons, sympathetic nerve manipulation, norepinephrine measurement, ADRB2+ macrophage identification and functional characterization, lethal pneumonia mouse model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic and pharmacologic manipulations of neural circuit and ADRB2 in macrophages, in vivo disease model with survival and cytokine readouts, circuit-level mechanistic dissection\",\n      \"pmids\": [\"40466637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADRB2 inhibition suppresses TGF-β1-induced fibroblast-to-myofibroblast differentiation by suppressing SMAD2/3 activation and increasing phospho-SMAD2/3 proteasome degradation. Conversely, ADRB2 enhancement induces fibroblast-to-myofibroblast differentiation. ADRB2 inhibition attenuated bleomycin-induced lung fibrosis in vivo.\",\n      \"method\": \"ADRB2 knockdown/overexpression in lung fibroblasts, pSMAD2/3 immunoblotting, proteasome inhibitor experiments, bleomycin mouse model\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic gain- and loss-of-function with specific SMAD2/3 phosphorylation readout and proteasome pathway identification, in vivo model corroboration, single lab\",\n      \"pmids\": [\"37923730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A functional SNP upstream of ADRB2 (rs34623097-A) reduces transcriptional activity of the ADRB2 promoter by approximately 10% and modulates nuclear factor binding affinity. The A allele was associated with increased obesity risk in Oceanic populations, consistent with reduced ADRB2 expression.\",\n      \"method\": \"Luciferase reporter assay comparing rs34623097-A vs. G allele, electrophoretic mobility shift assay (EMSA) for nuclear factor binding\",\n      \"journal\": \"International journal of obesity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — luciferase reporter assay and EMSA providing functional characterization of SNP, single lab with two orthogonal methods\",\n      \"pmids\": [\"23229733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A functional SNP upstream of ADRB2 (rs12654778) reduces relative ADRB2 promoter activity by ~26% (A vs. G allele) and modulates binding affinity of transcription factor neurofibromin 1 (NF1), establishing an allele-specific transcriptional regulatory mechanism linked to COPD susceptibility.\",\n      \"method\": \"Luciferase reporter assay, chromatin immunoprecipitation (ChIP) for NF1 binding, real-time PCR of ADRB2 expression in COPD patients vs. controls\",\n      \"journal\": \"International journal of chronic obstructive pulmonary disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — luciferase assay and ChIP demonstrating allele-specific promoter activity and TF binding, single lab with two orthogonal methods\",\n      \"pmids\": [\"29588580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADRB2 functions as an inhibitory checkpoint receptor on CAR-T cells. ADRB2 knockdown in CAR-T cells enhanced cytotoxicity against prostate cancer cells, increased CD69, CD107a, GzmB, IFN-γ, T-bet, and GLUT-1, improved proliferation, reduced apoptosis, and increased Bcl-2. The ZAP-70/NF-κB signaling axis was responsible for the improved functions. shβ2-CAR-T cells outperformed conventional CAR-T cells in vivo.\",\n      \"method\": \"RNAi knockdown of ADRB2 in CAR-T cells, cytotoxicity assays, flow cytometry for activation/exhaustion markers, ZAP-70/NF-κB pathway analysis, xenograft prostate cancer mouse model\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown with multiple functional readouts in vitro and in vivo, ZAP-70/NF-κB pathway mechanistically linked, single lab\",\n      \"pmids\": [\"39228124\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADRB2 (β2-adrenergic receptor) is a G-protein-coupled receptor that, upon activation by catecholamines, signals through cAMP/PKA and multiple downstream cascades (ERK/MAPK, PI3K/Akt, Gi protein) to regulate autophagy (by disrupting the Beclin1/VPS34/Atg14 complex), gene transcription (via CREB, NF-κB, AP-1, STAT3), lipid synthesis (via PKA/PPARγ), and protein stability (via PHD3 interaction and USP33-mediated deubiquitination); its expression is transcriptionally repressed by HIC1 and post-transcriptionally suppressed by miR-15a-5p and miR-16, while epigenetic silencing through promoter hypermethylation (e.g., induced by PM2.5) reduces receptor levels; in immune cells, ADRB2 acts as an inhibitory checkpoint on T cells through ZAP-70/NF-κB, and in ADRB2+ interstitial macrophages it amplifies inflammatory responses to sympathetic norepinephrine; in developmental contexts, neonatal β-cell ADRB2 restrains islet vascularization by suppressing VEGF-A, and in mesenchymal stem cells it promotes osteoclastogenesis and bone remodeling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ADRB2 (β2-adrenergic receptor) is a catecholamine-responsive G-protein-coupled receptor whose signaling output is reused across metabolic, immune, skeletal, and oncogenic contexts to control autophagy, transcription, cell proliferation, and protein stability [#0, #13, #15]. Through Akt-dependent signaling, ADRB2 disrupts the Beclin1/VPS34/Atg14 complex to suppress autophagy and stabilize HIF1α, reprogramming glucose metabolism and conferring sorafenib resistance in hepatocellular carcinoma [#0]; in a context-dependent manner its activation can instead restore autophagy-lysosomal function by upregulating VMA21/V-ATPase to mitigate amyloid-β pathology [#9]. In cancer cells, agonist-stimulated ADRB2 drives proliferation, invasion, and metastasis through the ERK1/2-JNK-MAPK cascade and the transcription factors NF-κB, AP-1, CREB, and STAT3 [#13], and through ADRB2/VEGFR2 interaction and a CREB/PSAT1 axis it promotes resistance to VEGFR2-targeted therapy [#12]. Through PKA-driven CREB phosphorylation it enhances PPARγ expression and lipid synthesis [#8], and through Gi coupling it transduces inhibitory signaling whose efficiency is allele-dependent [#11]. ADRB2 protein levels are set post-translationally: PHD3 binding destabilizes the receptor [#3], while USP33-mediated deubiquitination stabilizes it and is antagonized by the hepatokine ERAP1 to interrupt insulin signaling in skeletal muscle [#6]. ADRB2 expression is constrained transcriptionally by the repressor HIC1 [#1] and by promoter-proximal SNPs that modulate NF1 and other nuclear-factor binding [#17, #18], post-transcriptionally by miR-15a-5p targeting its 3'UTR [#14], and epigenetically by promoter hypermethylation [#10]. In immune cells ADRB2 acts as an inhibitory checkpoint, restraining T/CAR-T cell function through a ZAP-70/NF-κB axis [#19], while ADRB2+ interstitial macrophages near sympathetic nerves amplify norepinephrine-driven inflammation and lung injury [#15]. In development and skeletal biology, β-cell ADRB2 restrains islet vascularization by suppressing VEGF-A [#4] and mesenchymal-cell ADRB2 promotes osteoclastogenesis and bone remodeling [#2, #5].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Established that whole-gene sequence variation in ADRB2 determines how much receptor reaches the cell surface and how it is downregulated by agonist, framing ADRB2 function as haplotype-dependent.\",\n      \"evidence\": \"Whole-gene haplotype transfection into COS-7 cells with radioligand binding and agonist-promoted downregulation assays\",\n      \"pmids\": [\"20686604\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which individual polymorphisms drive the effect was not resolved\", \"No link to downstream signaling consequences\", \"Heterologous COS-7 system may not reflect native cell types\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified HIC1 as a direct transcriptional repressor of ADRB2, explaining how loss of a tumor suppressor de-represses ADRB2 to drive cancer cell migration and invasion.\",\n      \"evidence\": \"Promoter luciferase, ChIP and sequential ChIP, siRNA knockdown, and migration/invasion rescue in breast cancer cells\",\n      \"pmids\": [\"22194601\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream ADRB2 effectors mediating invasion not defined\", \"Whether HIC1 acts at the same elements as functional SNPs unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed a promoter SNP reduces ADRB2 transcription and alters nuclear-factor binding, providing a functional basis for genetic association with obesity.\",\n      \"evidence\": \"Luciferase reporter comparing alleles and EMSA for nuclear factor binding\",\n      \"pmids\": [\"23229733\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the bound nuclear factor not determined\", \"Causal link to obesity is associative, not mechanistic in vivo\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected mechanical force to ADRB2 induction and bone resorption, showing Adrb2 raises the RANKL/OPG ratio to drive osteoclastogenesis.\",\n      \"evidence\": \"Compressive force on primary PDLCs, Ca2+ measurement, co-culture osteoclastogenesis, Adrb1/2 knockout mice, ganglionectomy\",\n      \"pmids\": [\"25252876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling between ADRB2 and RANKL induction not detailed\", \"Cell-autonomy vs. neural contribution incompletely separated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a mechanism by which ADRB2 suppresses autophagy—disrupting the Beclin1/VPS34/Atg14 complex via Akt—to stabilize HIF1α and confer therapy resistance.\",\n      \"evidence\": \"Reciprocal Co-IP, immunoblot, knockdown/inhibitor studies in HCC lines and xenografts\",\n      \"pmids\": [\"27154061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ADRB2 activates Akt in this context not resolved\", \"Whether autophagy regulation generalizes beyond HCC unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed post-translational control of ADRB2 by PHD3, showing that blocking PHD3-ADRB2 interaction stabilizes the receptor to counter muscle atrophy.\",\n      \"evidence\": \"Co-IP of PHD3-ADRB2, PHD3 inhibition/knockdown, AKG rescue in corticosterone and DMD atrophy models\",\n      \"pmids\": [\"28939592\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PHD3 hydroxylates ADRB2 directly not established\", \"Single lab; reciprocal validation limited\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated developmental, sex-specific roles for β-cell ADRB2 in restraining islet vascularization through VEGF-A suppression, linking receptor loss to glucose intolerance.\",\n      \"evidence\": \"Pancreas-specific conditional Adrb2 knockout, glucose/insulin assays, VEGF-A measurement, VEGFR-blockade rescue\",\n      \"pmids\": [\"30303066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Basis of the female-specific phenotype unexplained\", \"Signaling linking ADRB2 to VEGF-A repression undefined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked the ADRB2 Gly16/Arg16 polymorphism to Gi-coupling efficiency and β-blocker responsiveness, establishing a genotype-dependent signaling determinant of therapy.\",\n      \"evidence\": \"In vitro Gi-coupling assays plus genotype-stratified multicenter heart-failure cohorts\",\n      \"pmids\": [\"30374408\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single mechanistic in vitro assay underpinning the clinical correlation\", \"Molecular basis of altered Gi coupling not structurally resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed an upstream SNP alters NF1 binding and ADRB2 promoter activity, providing an allele-specific transcriptional mechanism tied to COPD susceptibility.\",\n      \"evidence\": \"Luciferase reporter, ChIP for NF1 binding, and ADRB2 expression in COPD patients\",\n      \"pmids\": [\"29588580\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal contribution to COPD pathophysiology not demonstrated\", \"Whether NF1 regulation interacts with other repressors unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified ADRB2/VEGFR2 cross-talk and a CREB/PSAT1 axis as a driver of resistance to VEGFR2-TKIs in lung cancer, nominating ADRB2 blockade as a sensitizer.\",\n      \"evidence\": \"Co-IP of ADRB2/VEGFR2, propranolol treatment, CREB/PSAT1 analysis in NSCLC cells and xenografts\",\n      \"pmids\": [\"35075132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect nature of ADRB2/VEGFR2 interaction unresolved\", \"Single lab characterization\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapped the transcriptional output of cancer-cell ADRB2 activation to an ERK1/2-JNK-MAPK cascade engaging NF-κB, AP-1, CREB and STAT3, with receptor-subtype specificity.\",\n      \"evidence\": \"Subtype-specific pharmacology (ICI118,551 vs. atenolol), pathway analysis, xenograft stress model in gastric cancer\",\n      \"pmids\": [\"31624248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each transcription factor not dissected\", \"Effects on normal gastric epithelium untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established miR-15a-5p as a direct repressor of ADRB2 via its 3'UTR, defining a post-transcriptional brake that limits airway inflammatory gene expression.\",\n      \"evidence\": \"Luciferase reporter with WT/mutant 3'UTR, biotin pull-down, siRNA knockdown, ELISA in nasal epithelial cells\",\n      \"pmids\": [\"31104300\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of the miR-15a-5p/ADRB2 axis not tested\", \"Whether miR-16 acts identically not shown here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed that environmental epigenetic silencing of ADRB2 by promoter hypermethylation impairs PI3K/Akt signaling and triggers cardiomyocyte apoptosis.\",\n      \"evidence\": \"Methylation chip/BSP, ADRB2 overexpression, LY294002 inhibition, TUNEL, rat instillation model\",\n      \"pmids\": [\"30986742\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Enzymes driving the hypermethylation not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated that mesenchymal-cell ADRB2 promotes subchondral bone remodeling and osteoclastogenesis in joint osteoarthritis, extending its skeletal role to MSCs.\",\n      \"evidence\": \"Nestin-Cre x Adrb2 flox conditional knockout, crossbite model, histomorphometry and osteoclast quantification\",\n      \"pmids\": [\"31926929\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pro-osteoclastic mediators downstream of MSC ADRB2 not fully defined\", \"Relationship to RANKL/OPG mechanism from PDLCs not directly linked\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified the hepatokine ERAP1 and the deubiquitinase USP33 as opposing regulators of ADRB2 protein stability that gate insulin signaling in muscle.\",\n      \"evidence\": \"Reciprocal Co-IP of ERAP1-ADRB2, USP33 knockdown/overexpression, hepatic ERAP1 manipulation, insulin-sensitivity assays\",\n      \"pmids\": [\"35192681\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin ligase opposing USP33 not identified\", \"Site of ADRB2 ubiquitination unmapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked ADRB2/PKA/CREB signaling to PPARγ-driven lipid synthesis, defining a role in glandular lipid production.\",\n      \"evidence\": \"Agonist/antagonist pharmacology, CREB phosphorylation and PPARγ/SREBP-1 readouts, lipid staining in meibomian gland cells\",\n      \"pmids\": [\"36012741\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CREB directly drives PPARγ transcription not shown\", \"Single cell-type, single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed ADRB2 promotes fibroblast-to-myofibroblast differentiation by stabilizing SMAD2/3, with inhibition attenuating lung fibrosis.\",\n      \"evidence\": \"ADRB2 gain/loss in lung fibroblasts, pSMAD2/3 immunoblot, proteasome inhibition, bleomycin mouse model\",\n      \"pmids\": [\"37923730\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ADRB2 controls SMAD2/3 proteasomal degradation mechanistically unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Found that ADRB2 activation by exercise can restore autophagy-lysosomal function via VMA21/V-ATPase to reduce amyloid pathology, an autophagy-promoting role contrasting its HCC autophagy-suppressing role.\",\n      \"evidence\": \"Exercise intervention and propranolol blockade in APP-PSEN1 mice, AMPK-mTOR/VMA21 analysis, amyloid and cognition readouts\",\n      \"pmids\": [\"37964627\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reconciliation with autophagy-suppressing role in cancer unresolved\", \"Direct link from ADRB2 to VMA21 not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined ADRB2 as an inhibitory checkpoint on CAR-T cells acting through a ZAP-70/NF-κB axis, nominating its knockdown to enhance anti-tumor T-cell function.\",\n      \"evidence\": \"RNAi knockdown in CAR-T cells, cytotoxicity and activation/exhaustion marker profiling, ZAP-70/NF-κB analysis, prostate cancer xenografts\",\n      \"pmids\": [\"39228124\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ADRB2 couples to ZAP-70 not resolved\", \"Endogenous catecholamine source in tumor not addressed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placed ADRB2 in a neuroimmune circuit, showing ADRB2+ interstitial macrophages sense sympathetic norepinephrine to amplify lung inflammation during pneumonia.\",\n      \"evidence\": \"Opto/chemogenetic neural-circuit manipulation, norepinephrine measurement, ADRB2+ macrophage functional characterization, lethal pneumonia model\",\n      \"pmids\": [\"40466637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling from ADRB2 to cytokine output in macrophages not detailed\", \"Generalizability beyond severe pneumonia unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ADRB2 signaling is rerouted to opposite outcomes in different cell types—autophagy suppression vs. promotion, pro- vs. anti-inflammatory effects—remains unresolved at the level of cell-type-specific effector wiring.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying account of context-dependent G-protein/effector coupling\", \"Structural basis for allele- and cell-type-specific signaling unmapped\", \"Endogenous ligand source and concentration in each tissue often inferred rather than measured\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 11, 13]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [19, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 11, 13]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19, 15]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 17, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"PHD3\", \"USP33\", \"ERAP1\", \"VEGFR2\", \"HIC1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}